Free Trial
NASDAQ:SLRN

Acelyrin (SLRN) Stock Price, News & Analysis

Acelyrin logo
$2.60 +0.43 (+19.82%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$2.60 +0.00 (+0.19%)
As of 02/21/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Acelyrin Stock (NASDAQ:SLRN)

Key Stats

Today's Range
$2.37
$2.64
50-Day Range
$1.89
$3.82
52-Week Range
$1.85
$8.89
Volume
12.57 million shs
Average Volume
2.60 million shs
Market Capitalization
$260.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60
Consensus Rating
Hold

Company Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Acelyrin Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

SLRN MarketRank™: 

Acelyrin scored higher than 57% of companies evaluated by MarketBeat, and ranked 460th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Acelyrin has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Acelyrin has only been the subject of 3 research reports in the past 90 days.

  • Read more about Acelyrin's stock forecast and price target.
  • Earnings Growth

    Earnings for Acelyrin are expected to grow in the coming year, from ($2.53) to ($2.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acelyrin is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acelyrin is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acelyrin has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Acelyrin's valuation and earnings.
  • Percentage of Shares Shorted

    8.09% of the float of Acelyrin has been sold short.
  • Short Interest Ratio / Days to Cover

    Acelyrin has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Acelyrin has recently decreased by 10.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Acelyrin does not currently pay a dividend.

  • Dividend Growth

    Acelyrin does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.09% of the float of Acelyrin has been sold short.
  • Short Interest Ratio / Days to Cover

    Acelyrin has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Acelyrin has recently decreased by 10.11%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Acelyrin has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Acelyrin this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for SLRN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Acelyrin insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acelyrin's insider trading history.
Receive SLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter.

SLRN Stock News Headlines

Acelyrin Stock Jumps on Concentra Acquisition Interest
Acelyrin Stock Jumps on Concentra Acquisition Interest
Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences
See More Headlines

SLRN Stock Analysis - Frequently Asked Questions

Acelyrin's stock was trading at $3.14 on January 1st, 2025. Since then, SLRN stock has decreased by 17.2% and is now trading at $2.60.
View the best growth stocks for 2025 here
.

Acelyrin, Inc. (NASDAQ:SLRN) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.08.

Acelyrin (SLRN) raised $540 million in an IPO on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share.

Top institutional shareholders of Acelyrin include T. Rowe Price Investment Management Inc. (12.83%), Millennium Management LLC (4.70%), venBio Partners LLC (3.79%) and Blue Owl Capital Holdings LP (2.77%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg, Daniel J Becker and Ronald Oyston.
View institutional ownership trends
.

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acelyrin investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Netflix (NFLX).

Company Calendar

Last Earnings
8/13/2024
Today
2/22/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLRN
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.60
High Stock Price Target
$20.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+269.2%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-381,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.74 per share

Miscellaneous

Free Float
86,682,000
Market Cap
$260.86 million
Optionable
Optionable
Beta
1.85
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:SLRN) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners